Güner Hayri Özsan

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells

Seda Baykal, Eda Açıkgöz, Ahmet Sinan Yavuz et al. · PLoS ONE · 2020 · 58 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers

İnci Alacacıoğlu, Güner Hayri Özsan, Bahriye Payzın et al. · Chemotherapy · 2014 · 29 citations

Medicine, Hematology, Oncology +14

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy

Jan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul et al. · British Journal of Haematology · 2018 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Can Neutrophil‐to‐Lymphocyte Ratio, Monocyte‐to‐Lymphocyte Ratio, and Platelet‐to‐Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Şerife Solmaz, Celal Acar, Aybüke Olgun et al. · Clinical Transplantation · 2018 · 26 citations

Medicine, Hematology, Oncology +14